Management of Type 2 Diabetes in Acute Coronary Syndromes: Current State and Future Perspectives

Curr Pharm Des. 2023;29(5):365-367. doi: 10.2174/1381612829666230210161306.

Authors

Theocharis Koufakis¹, Dimos Karangelis², Vasiliki Androutsopoulou², Dimitrios Mikroulis², Kalliopi Kotsa¹

Affiliations

¹ Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
² Department of Cardiac Surgery, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

PMID: 36762749
DOI: 10.2174/1381612829666230210161306

No abstract available

Keywords: Diabetes; GLP-1 receptor agonists; SGLT2 inhibitors; acute coronary syndrome; acute myocardial infarction; insulin.

Publication types

Editorial

MeSH terms

Acute Coronary Syndrome* / drug therapy
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / therapeutic use
Risk Factors

Substances

Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor